RENMAB Trademark

Trademark Overview

On Wednesday, July 31, 2019, a trademark application was filed for RENMAB with the United States Patent and Trademark Office. The USPTO has given the RENMAB trademark a serial number of 88553807. The federal status of this trademark filing is SU - REGISTRATION REVIEW COMPLETE as of Thursday, December 18, 2025. This trademark is owned by Beijing Biocytogen Co., Ltd.. The RENMAB trademark is filed in the Pharmaceutical Products category with the following description:

Medical immunoassay reagent derived from experimental animals; medical biological preparations for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; drugs for treating cancer, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; medicines for human purposes, namely, for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; biochemical drugs for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; immunologic stimulants for medical use for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; bulk drugs for the treatment of diseases, namely, Active Biopharmaceutical Ingredients derived from experimental animals; medical diagnostic preparation, namely, antibodies and proteins for biopharmaceuticals ...
renmab

General Information

Serial Number88553807
Word MarkRENMAB
Filing DateWednesday, July 31, 2019
Status819 - SU - REGISTRATION REVIEW COMPLETE
Status DateThursday, December 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 17, 2021

Trademark Statements

Goods and ServicesMedical immunoassay reagent derived from experimental animals; medical biological preparations for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; drugs for treating cancer, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; medicines for human purposes, namely, for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; biochemical drugs for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; immunologic stimulants for medical use for the treatment of diseases, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals; bulk drugs for the treatment of diseases, namely, Active Biopharmaceutical Ingredients derived from experimental animals; medical diagnostic preparation, namely, antibodies and proteins for biopharmaceuticals derived from experimental animals
Translation of Words in MarkThe wording "RENMAB" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 14, 2019
Primary Code005
First Use Anywhere DateMonday, June 1, 2020
First Use In Commerce DateMonday, June 1, 2020

Trademark Owner History

Party NameBIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDaxing District, Beijing 102609
CN
Party NameBIOCYTOGEN PHARMACEUTICALS (BEIJING) CO.
Party Type11 - New Owner Before Publication
Legal Entity Type99 - Other
AddressBEIJING 100176
CN
Party NameBeijing Biocytogen Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBeijing 100176
CN

Trademark Events

Event DateEvent Description
Saturday, August 3, 2019NEW APPLICATION ENTERED
Wednesday, August 14, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, October 28, 2019ASSIGNED TO EXAMINER
Tuesday, November 5, 2019NON-FINAL ACTION WRITTEN
Tuesday, November 5, 2019NON-FINAL ACTION E-MAILED
Tuesday, November 5, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 8, 2020ASSIGNED TO LIE
Tuesday, May 12, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 12, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 29, 2020SUSPENSION LETTER WRITTEN
Friday, May 29, 2020LETTER OF SUSPENSION E-MAILED
Friday, May 29, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, December 2, 2020SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Tuesday, January 5, 2021SUSPENSION INQUIRY WRITTEN
Tuesday, January 5, 2021INQUIRY TO SUSPENSION E-MAILED
Tuesday, January 5, 2021NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Wednesday, February 17, 2021AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, July 6, 2021TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Friday, July 9, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 9, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 28, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 17, 2021PUBLISHED FOR OPPOSITION
Tuesday, August 17, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, September 15, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Monday, February 14, 2022OPPOSITION INSTITUTED NO. 999999
Monday, October 21, 2024OPPOSITION DISMISSED NO. 999999
Monday, October 21, 2024OPPOSITION TERMINATED NO. 999999
Monday, October 21, 2024TTAB RELEASE CASE TO TRADEMARKS
Tuesday, November 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 1, 2025TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, May 13, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, May 18, 2025TEAS REQUEST TO DIVIDE RECEIVED
Monday, May 19, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, October 1, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, May 18, 2025SOU EXTENSION 1 FILED
Wednesday, October 1, 2025SOU EXTENSION 1 GRANTED
Thursday, October 2, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 23, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sunday, May 18, 2025DIVISIONAL REQUEST RECEIVED
Monday, October 27, 2025DIVISIONAL PROCESSING COMPLETE
Thursday, November 13, 2025TEAS STATEMENT OF USE RECEIVED
Thursday, November 13, 2025USE AMENDMENT FILED
Friday, November 14, 2025STATEMENT OF USE PROCESSING COMPLETE
Thursday, December 18, 2025ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, December 18, 2025NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

Related Keywords

renmab namely experimental animals from derived proteins antibodies biopharmaceuticals treatment diseases